Wire Stories

Daiichi Sankyo and AstraZeneca�s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients…

4 years ago

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

� Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate � � 87.5% of Responses Achieved in First…

4 years ago

Cubic Technology Launched to Provide Easier Rail Journeys for Queensland Commuters

Cubic Transportation Systems launches the first credit card and smart device-compatible gates on Queensland's Heavy Rail Network, giving more payment…

4 years ago

INDIANAPOLIS, June 03, 2022 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) announced today that it will present at…

4 years ago

Global Commercial Vehicle Surround View System Markets, 2021-2030: Revenue, Trends, Growth Opportunities, Competition, End Cases – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Commercial Vehicle Surround View System Market - Revenue, Trends, Growth Opportunities, Competition, COVID-19 Strategies, Regional Analysis and Future…

4 years ago

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3…

4 years ago

Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer

Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral…

4 years ago

Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer

Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral…

4 years ago

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3…

4 years ago

OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars

SUWON, South Korea--(BUSINESS WIRE)--#ClinicalTrial--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient…

4 years ago
Show more Posts
Show previous Posts